Corteva (CTVA) investor relations material

Regulatory and industry developments

• EU Parliament approved new gene editing policy, enabling cultivation and importation of gene-edited crops in Europe after a 30-year GMO ban, with implementation expected over the next two years.

• The regulatory shift in Europe is expected to influence global standards and facilitate broader acceptance of gene editing in other markets, including China.

• Recent settlement with Bayer resolved longstanding litigation, accelerating product launches and reducing licensing expenses, improving financial certainty.

Technology and innovation

• Gene editing enables development of multi-disease-resistant corn and other crops, offering yield improvements and simplified crop management.

• Proprietary germplasm and the Genlytix IP ecosystem provide a strong foundation for innovation and licensing opportunities.

• AI integration in breeding and manufacturing accelerates product development, enhances decision-making, and optimizes seed production at scale.

• Hybrid wheat technology is nearing commercial launch, with potential to transform wheat production globally.

Strategic direction and business model

• The seed business spin-off aims to unlock value through focused strategy, capital deployment, and operational efficiency tailored to regional and global needs.

• Transition from in-licensed to proprietary biotech traits is reducing royalty expenses and improving margins, with a $1 billion opportunity projected by mid-next decade.

• Dyssynergies from the separation are trending more favorable than initial estimates, with cost savings from restructuring and right-sizing.

• Near-term growth will be driven by GMOs and germplasm, with gene editing and hybrid wheat becoming more material in the mid-2030s and beyond.